Ramosetron in Irritable Bowel Syndrome With Diarrhea: New Hope or the Same Old Story?

Clinical Gastroenterology and Hepatology

Volumn 12, Issue 6, 2014, Pages 960-962

  Grover, Madhusudan ^a   Camilleri, Michael ^a  

^a Clinical Enteric Neuroscience Translational and Epidemiological Research Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON; AST 120; CROMOGLYCATE DISODIUM; DARIFENACIN; GRANISETRON; KETOTIFEN; LX 1031; ONDANSETRON; OTILONIUM BROMIDE; RAMOSETRON; SEROTONIN 3 RECEPTOR; SOLIFENACIN; UNCLASSIFIED DRUG; BENZIMIDAZOLE DERIVATIVE; GASTROINTESTINAL AGENT;

CHRONIC DIARRHEA; CLINICAL TRIAL (TOPIC); COLON MOTILITY; DEFECATION; DIARRHEA; DRUG EFFICACY; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HUMAN; IRRITABLE COLON; ISCHEMIC COLITIS; MULTICENTER STUDY (TOPIC); NONHUMAN; PAIN THRESHOLD; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); ANIMAL; COMPLICATION; FECES; IRRITABLE BOWEL SYNDROME; MALE; PHYSICAL CHEMISTRY;

ANIMALS; BENZIMIDAZOLES; DIARRHEA; FECES; GASTROINTESTINAL AGENTS; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; PHYSICOCHEMICAL PHENOMENA;

EID: 84901233892     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2013.12.025     Document Type: Editorial

References (29)

1. Camilleri M. Current and future pharmacological treatments for diarrhea-predominant irritable bowel syndrome. Expert Opin Pharmacother 2013, 14:1151-1160.
2. Andresen V., Montori V.M., Keller J., et al. Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. Clin Gastroenterol Hepatol 2008, 6:545-555.
3. Ford A.C., Brandt L.J., Young C., et al. Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol 2009, 104:1831-1843. quiz 1844.
4. Saslow S.B., Scolapio J.S., Camilleri M., et al. Medium-term effects of a new 5HT3 antagonist, alosetron, in patients with carcinoid diarrhoea. Gut 1998, 42:628-634.
5. Talley N.J., Phillips S.F., Haddad A., et al. GR 38032F (ondansetron), a selective 5HT3 receptor antagonist, slows colonic transit in healthy man. Dig Dis Sci 1990, 35:477-480.
6. Bjornsson E.S., Chey W.D., Ladabaum U., et al. Differential 5-HT3 mediation of human gastrocolonic response and colonic peristaltic reflex. Am J Physiol 1998, 275:G498-G505.
7. Prior A., Read N.W. Reduction of rectal sensitivity and post-prandial motility by granisetron, a 5 HT3-receptor antagonist, in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1993, 7:175-180.
8. Cremonini F., Nicandro J.P., Atkinson V., et al. Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea-predominant IBS. Aliment Pharmacol Ther 2012, 36:437-448.
9. Tong K., Nicandro J.P., Shringarpure R., et al. A9-year evaluation of temporal trends in alosetron postmarketing safety under the risk management program. Ther Adv Gastroenterol 2013, 6:344-357.
10. Camilleri M. Is there an experimental basis for the development of ischaemic colitis as a result of 5-HT3 antagonist treatment?. Neurogastroenterol Motil 2007, 19:77-84.
11. Painsipp E., Shahbazian A., Holzer P. Alosetron, cilansetron and tegaserod modify mesenteric but not colonic blood flow in rats. Br J Pharmacol 2009, 158:1210-1226.
12. Lewis J.H. The risk of ischaemic colitis in irritable bowel syndrome patients treated with serotonergic therapies. Drug Saf 2011, 34:545-565.
13. Fukudo S., Ida M., Akiho H., et al. Effect of ramosetron on stool consistency in male patients with irritable bowel syndrome with diarrhea. Clin Gastroenterol Hepatol 2014, 12:953-959.
14. Miyata K., Kamato T., Nishida A., et al. Pharmacologic profile of (R)-5-[(1-methyl-3-indolyl)carbonyl]-4,5,6,7-tetrahydro-1H- benzimidazole hydrochloride (YM060), a potent and selective 5-hydroxytryptamine3 receptor antagonist, and its enantiomer in the isolated tissue. JPharmacol Exp Ther 1991, 259:15-21.
15. Miyata K., Kamato T., Nishida A., et al. Role of the serotonin3 receptor in stress-induced defecation. JPharmacol Exp Ther 1992, 261:297-303.
16. Miyata K., Ito H., Fukudo S. Involvement of the 5-HT3 receptor in CRH-induce defecation in rats. Am J Physiol 1998, 274:G827-G831.
17. Hirata T., Keto Y., Nakata M., et al. Effects of serotonin 5-HT3 receptor antagonists on stress-induced colonic hyperalgesia and diarrhoea in rats: a comparative study with opioid receptor agonists, a muscarinic receptor antagonist and a synthetic polymer. Neurogastroenterol Motil 2008, 20:557-565.
18. Matsueda K., Harasawa S., Hongo M., et al. Aphase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome. Digestion 2008, 77:225-235.
19. Chiba T., Yamamoto K., Sato S., et al. Long-term efficacy and safety of ramosetron in the treatment of diarrhea-predominant irritable bowel syndrome. Clin Exp Gastroenterol 2013, 6:123-128.
20. US Department of Health and Human services Food and Drug Administration Center for Drug Evaluation and research (CDER). Guidance for industry. Irritable bowel syndrome-clinical evaluation of drugs for treatment 2012. Available at: Accessed: December 11,2013. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm205269.pdf.
21. Delvaux M., Louvel D., Mamet J.P., et al. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1998, 12:849-855.
22. Hicks G.A., Coldwell J.R., Schindler M., et al. Excitation of rat colonic afferent fibres by 5-HT(3) receptors. JPhysiol 2002, 544:861-869.
23. Bradesi S., Lao L., McLean P.G., et al. Dual role of 5-HT3 receptors in a rat model of delayed stress-induced visceral hyperalgesia. Pain 2007, 130:56-65.
24. Chang L., Ameen V.Z., Dukes G.E., et al. Adose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. Am J Gastroenterol 2005, 100:115-123.
25. Viramontes B.E., Camilleri M., McKinzie S., et al. Gender-related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2001, 96:2671-2676.
26. Koch K.M., Corrigan B.W., Manzo J., et al. Alosetron repeat dose pharmacokinetics, effects on enzyme activities, and influence of demographic factors. Aliment Pharmacol Ther 2004, 20:223-230.
27. Camilleri M., Atanasova E., Carlson P.J., et al. Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Gastroenterology 2002, 123:425-432.
28. Berman S., Munakata J., Naliboff B.D., et al. Gender differences in regional brain response to visceral pressure in IBS patients. Eur J Pain 2000, 4:157-172.
29. Naliboff B.D., Berman S., Chang L., et al. Sex-related differences in IBS patients: central processing of visceral stimuli. Gastroenterology 2003, 124:1738-1747.